Oral Wegovy’s UK Rollout Puts Novo Nordisk’s Pivot to the Pill to the Test
Novo Nordisk’s long-anticipated shift from injection to tablet enters its most public phase this week, with the oral…
Novo Nordisk’s Pipeline Verdict Looms as Wegovy’s Formulary Edge Crumbles and Buybacks Fall Shor
As commercial pressures mount from Lilly rivals and patent expiries, Novo Nordisk’s upcoming data readouts for CagriSema and…
Amid Wegovy’s EU Endorsement, Novo Nordisk Grapples with a Rising Tide of Litigation and a Critical
EU approves higher-dose Wegovy, but CVS Caremark favors Eli Lilly drugs, legal claims over blindness risk mount, and…
Novo Nordisk Juggles Lilly’s Clinical Challenge and Wegovy’s Indian Opportunity
Novo Nordisk’s stock barely moves as Eli Lilly’s superior trial data pressures GLP-1 business, but India’s Wegovy approval…